Skip to content
drillr.ai
Sign up

QNRX

Quoin Pharmaceuticals, Ltd.

NASDAQ · Healthcare · Biotechnology · US

$7.06
+0.71%
Ask drillr

  • Sep 8, 2026, 12:30 UTC

    The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Quoin Pharmaceuticals' QRX003 for the treatment of Peeling Skin Syndrome, the second such designation for the drug after a prior one for Netherton Syndrome.

    Source:

  • Aug 28, 2026, 13:40 UTC

    Quoin Pharmaceuticals announced positive clinical trial results for its product on Friday morning.

    Source:

  • Aug 28, 2026, 10:00 UTC

    Quoin Pharmaceuticals entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds through a private placement of ordinary shares and warrants.

    Source:

  • Aug 20, 2026, 00:00 UTC

    Quoin Pharmaceuticals, Ltd. elected Dr. Michael Myers, Denise Carter, Joseph Cooper, James Culverwell, and Dr. Dennis H. Langer as directors, effective August 20, 2026.

  • Aug 14, 2026, 12:30 UTC

    Quoin Pharmaceuticals received FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome, received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, and submitted an IND for Peeling Skin Syndrome with FDA clearance received after quarter end.

    Source:

  • Aug 14, 2026, 00:00 UTC

    Quoin Pharmaceuticals reported a net loss of approximately $5.4 million for Q2 2026, with diluted EPS of -$1.90, and a net loss of approximately $10.4 million for the first half of 2026.

  • Aug 7, 2026, 12:30 UTC

    Quoin Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a corporate update on August 14, 2026.

    Source:

  • Jun 30, 2026, 12:30 UTC

    Quoin Pharmaceuticals received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome.

    Source:

  • Jun 18, 2026, 12:30 UTC

    Quoin Pharmaceuticals completed the establishment of a Japanese subsidiary to advance commercial readiness for QRX003.

    Source:

  • Jun 5, 2026, 05:57 UTC

    Quoin Pharmaceuticals received orphan drug designation for QRX003 from Japan's Ministry of Health, Labour and Welfare for treating Netherton Syndrome.

    Source:

  • Jun 2, 2026, 12:30 UTC

    Quoin Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA for QRX003 to treat Peeling Skin Syndrome.

    Source: